The Role and Place of Metabolic Radiation Methods in the Assessment of Therapeutic Pathomorphism of Breast Cancer and Prognosis of the Course of the Disease

The aim of the study was to evaluate the effectiveness of single-voxel proton magnetic resonance spectroscopy (SV 1H-MRS), combined positron emission and computed tomography (PET/CT) scans in determining the prognosis of breast cancer, the nature of therapeutic pathomorphism under the influence of neoadjuvant therapy. The supervision period lasted from 2015 to 2020. There were 112 breast cancer patients aged 30 to 83 years (mean age 53,3 ± 11,2 years [54 (45; 59)], 95 % CI: 51.2-55.4), who were divided into 2 study groups depending on the survey design. The 1st group consisted of 77 (68,75%) patients who have had single-voxel proton magnetic resonance spectroscopy added to the standard protocol of multiparametric magnetic resonance imaging of the mammary glands (mpMRI MG). In the 2nd group of 35 (31,25%) patients, PET/CT scans of the whole body with 18F-fluorodeoxyglucose (18F-FDG) were performed in addition to the standard study. In the course of the observation, it was proved in dynamics that it is advisable to carry out an mpMRI with SV 1H-MRS during the initial examination of breast cancer patients since it has higher accuracy (Ac = 98,3 %, 95 % CI: 86,3-100,0 ) compared with PET/CT in assessing the local prevalence of tumors, their size, structure and vascularization. The peak of total choline (tCho) determined with SV 1H-MRS should be considered as one of the metabolites - predictors of an unfavorable prognosis of the course of the disease.

Breast Cancer, Multiparametric Magnetic Resonance Imaging, Single-Voxel Proton Magnetic Resonance Spectroscopy, Combined Positron Emission And Computed Tomography

1. Гележе П. Б., Морозов С. П. Возможности применения магнитно-резонансной томографии и позитронно-эмиссионной томографии с 18F-фтордезоксиглюкозой для диагностики рака молочной железы (обзор литературы и собственные клинические наблюдения) // Радиология - практика. 2018. № 6 (72). С. 22-35.

2. Демшина Т. Е., Рязанов В. В., Серебрякова C. B., Бойков И. В. Возможности ПЭТ/КТ в диагностике и оценке распространенности рака молочной железы // Невский радиологический форум. СПб., 2011. С. 63.

3. Карпова М. С., Алиева Г. С., Петровский А. В., Корженкова Г. П. Возможности магнитно-резонансной маммографии в диагностике неинвазивного протокового рака молочной железы (обзор литературы и собственный опыт использования) // Радиология - практика. 2017. № 6 (66). С. 60-70.

4. Меладзе Н. В., Шария М. А., Устюжанин Д. В., Терновой С. К. Роль магнитно-резонансной маммографии и магнитно-резонансной спектроскопии в дифференциальной диагностике новообразований молочной железы // Вестник рентгенологии и радиологии. 2018. № 99 (1). С. 13-22. https://doi.org/10.20862/0042-4676-2018-99-1-13-22.

5. Ненахова Ю. Н., Лядов В. К., Поддубная И. В. Циркулирующие опухолевые клетки: биология, методы выделения, клиническое значение при раке молочной железы // Современная онкология. 2016. № 3. С. 76-82.

6. Серебрякова С. В., Труфанов Г. Е., Фокин В. А., Юхно Е. А. Магнитно-резонансная томография с контрастным усилением в дифференциальной диагностике узловых образований молочных желез // Трансляционная медицина. 2016. № 3(5). С. 82-94. https://doi.org/10.18705/2311-4495-2016-3-5-82-94.

7. Хоружик С.А., Шиманец С.В., Карман А.В., Шаповал Е.В. Использование системы BI-RADS для интерпретации данных магнитно-резонансной маммографии при раке молочной железы // Вестник рентгенологии и радиологии. 2014. № 4. С. 46-59. https://doi.org/ 10.20862/0042-4676-2014-0-4-46-59.

8. Cao Q., Hersl J., La H. et al. A pilot study of FDG PET/CT detects a link between brown adipose tissue and breast cancer // BMC Cancer. 2014. V. 14. Р. 126. https://doi.org/10.1186/1471-2407-14-126.

9. Groheux D., Giacchetti S., Delord M. et al. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: Comparison to conventional staging // J. Nucl. Med. 2013. V. 54. Р. 5-11. https://doi.org/ 10.2967/jnumed.112.106864.

10. Menezes G., Knuttel F., Stehouwer B. et al. Magnetic resonance imaging in breast cancer: A literature review and future perspectives // World J. Clin. Oncol. 2014. V. 5. № 2. P. 61-70.

11. Jagannathan N. R., Kumar M., Seenu V., Coshic O., Dwivedi S. N., Julka P. K., Srivastava A., Rath G. K. Evaluation of total choline from in vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer // Br. J. Cancer. 2001. V. 84. Р. 1016-1022. https://doi.org/10.1054/bjoc.2000.1711. References

12. Gelizhe P. B., Morozov S. P. The possibility of applying magnetic resonance imaging and positron emission tomography with 18F-fluorodeoxyglucose for the diagnosis of breast cancer (literature review and own clinical observation). Radiologiya - praktika. 2018. No. 6 (72). P. 22-35 (in Russian).

13. Demshina T. E., Ryazanov V. V., Serebryakova C. B., Boikov I. V. Possibilities of PET/CT in the diagnosis and assessment of the prevalence of breast cancer. Nevsky radiological forum. Saint-Petersburg. 2011. P. 63 (in Russian).

14. Karpova M. S., Aliyeva G. S., Petrovsky A.V., Korzhenkova G. P. Possibilities of magnetic resonance mammography in the diagnosis of non-invasive ductal breast cancer (literature review and own experience of use. Radiologiya - praktika, 2017. № 6 (66). Р. 60-70 (in Russian).

15. Meladze N. V., Sharia M. A., Ustyuzhanin D. V., Ternovoy S. K. The role of magnetic resonance mammography and magnetic resonance spectroscopy in the differential diagnosis of breast tumors. Vestnik roentgenologiya i radiologiya. 2018. No. 99 (1). P. 13-22. https://doi.org/10.20862/0042-4676-2018-99-1-13-22 (in Russian).

16. Nenakhova Yu. N., Lyadov V. K., Poddubnaya I. V. Circulating tumor cells: biology, isolation methods, clinical significance in breast cancer. Sovremennaya onkologiya. 2016. No. 3. P. 76-82 (in Russian).

17. Serebryakova S. V., Trufanov G. E., Fokin V. A., Yukhno E. A. The magnetic resonance mammography with dynamic contrastenh ancement in the differential diagnostics of breast nodes. Translational Medicine. 2016. No. 3 (5). Р. 82-94. https://doi.org/10.18705/2311-4495-2016-3-5-82-94 (in Russian).

18. Kharuzhyk S. A., Shymanets S. V., Karman A. V., Shapoval E. V. Use of BI-RADS to interpret magnetic resonance mammography for breast cancer vestnik rentgenologii i radiologii. 2014. No. 4. Р. 46-59. https://doi.org/10.20862/ 0042-4676-2014-0-4-46-59 (in Russian).

19. Cao Q., Hersl J., La H. et al. A pilot study of FDG PET/CT detects a link between brown adipose tissue and breast cancer. BMC Cancer. 2014. V. 14. Р. 126. https://doi.org/10.1186/1471-2407-14-126.

20. Groheux D., Giacchetti S., Delord M. et al. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: Comparison to conventional staging. J. Nucl. Med. 2013. V. 54. Р. 5-11. https://doi.org/10.2967/jnumed. 112.106864.

21. Menezes G., Knuttel F., Stehouwer B. et al. Magnetic resonance imaging in breast cancer: A literature review and future perspectives. World J. Clin. Oncol. 2014. V. 5. No. 2. P. 61-70.

22. Jagannathan N. R., Kumar M., Seenu V., Coshic O., Dwivedi S. N., Julka P. K., Srivastava A., Rath G. K. Evaluation of total choline from in vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer. 2001. V. 84. Р. 1016-1022. https://doi.org/10.1054/bjoc.2000.1711.